Nu-Med Plus Develops Portable Rapid Distribution Nitric Oxide Generator

SALT LAKE CITY, UT--(Marketwired - January 14, 2016) - Nu-Med Plus, Inc. (OTCBB: NUMD), a medical device development company, announced the development of a new delivery system and formulation for the generation of inhaled nitric oxide for potential therapeutic use outside the hospital and clinical environment. The newly developed system uses the thermal decomposition of a complex compound as the source of nitric oxide.

Nitric Oxide (NO) is an essential biological gas which is currently being used for congenital pulmonary hypoplasia and neonatal hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. Jeff Robins, President and CEO of Nu-Med Plus, Inc. commented, "This newly developed Inhaled Nitric Oxide generation concept has vast potential for a very portable unit that could be used by an individual when there is an instantaneous and critical necessity for the administration of the gas."

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. is a medical device development company created to explore medical applications of newly developed technologies. The strategy is to focus on high growth potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more company information please visit www.nu-medplus.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.